BC Extra | Sep 10, 2019
Company News

Sept. 10 Company Quick Takes: Lexicon, Sanofi part ways on diabetes drug; plus Mesoblast-Gruenenthal, Mateon-WideTrial, Intra-Cellular

Sanofi to pay Lexicon $260M as Zynquista ends  Sanofi (NASDAQ:SNY) will pay Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) $208 million up front plus $52 million over the next 12 months as part of the companies’ agreement to...
BC Week In Review | Oct 6, 2017
Clinical News

Mateon discontinuing Zybrestat on Phase II/III ovarian cancer data

Mateon Therapeutics Inc. (OTCQX:MATN) discontinued development of Zybrestat fosbretabulin (combretastatin A4P, CA4P) after data from the first 70 platinum-resistant ovarian cancer patients enrolled in the Phase II/III FOCUS trial showed Zybrestat in combination with physician’s...
BC Week In Review | Sep 1, 2017
Clinical News

Mateon reports interim Phase II/III data for Zybrestat in ovarian cancer

Mateon Therapeutics Inc. (OTCQX:MATN) reported data from a second scheduled interim analysis of the first 40 patients with platinum resistant ovarian cancer in the Phase II/III FOCUS trial of Zybrestat fosbretabulin (combretastatin A4P, CA4P) to...
BC Week In Review | May 19, 2017
Financial News

Mateon proposes $8M follow-on

On May 11, cancer company Mateon Therapeutics Inc. (OTCQX:MATN) proposed to raise $8 million in a follow-on underwritten by H.C. Wainwright. Mateon Therapeutics Inc. (OTCQX:MATN), South San Francisco, Calif. ...
BC Innovations | May 16, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture studies suggest that artificial vesicles loaded with Zybrestat fosbretabulin and doxorubicin could help treat doxorubicin-resistant breast cancer. The artificial vesicles consisted of amphiphilic block co-polymers loaded with Zybrestat fosbretabulin and...
BC Week In Review | Apr 28, 2017
Clinical News

Fosbretabulin: Ph I Study MCC-2016-088 started

Mateon said investigators at the University of Kentucky (Lexington, Ky.) began the open-label, U.S. Phase I Study MCC-2016-088 to evaluate IV fosbretabulin plus Afinitor everolimus for 12 weeks in about 30 patients who progressed following...
BC Week In Review | Jan 27, 2017
Clinical News

Zybrestat: Final Ph II Study OX4218 data

Final data from the open-label, U.S. Phase II Study OX4218 in 18 patients with well-differentiated, low-to-intermediate-grade, unresectable, recurrent or metastatic PNETs or GI-NETs showed that 60 mg/m 2 IV Zybrestat on days 1, 8 and...
BC Week In Review | Jul 11, 2016
Clinical News

Fosbretabulin: Phase II/III started

Mateon began the double-blind, placebo-controlled, U.S. Phase II/III FOCUS trial to evaluate 60 mg/m 2 CA4P on days 1 and 15 of a 28-day cycle plus physician’s choice of chemotherapy plus Avastin bevacizumab in about...
BC Week In Review | Nov 23, 2015
Clinical News

Fosbretabulin: Preliminary Phase Ib data

Preliminary data from 9 evaluable patients with advanced recurrent ovarian cancer in the dose-escalation Phase Ib portion of the open-label, U.K. Phase Ib/II PAZOFOS trial showed that once-weekly 45-60 mg/m 2 IV Zybrestat for 3...
BC Week In Review | Nov 2, 2015
Clinical News

OXi4503 combretastatin A1 di-phosphate: Phase Ib/II started

OxiGene began an open-label, U.S. Phase Ib/II trial to evaluate OXi4503 as a single agent and in combination with intermediate-dose cytarabine. The dose-escalation Phase Ib portion will enroll up to 27 patients and the Phase...
Items per page:
1 - 10 of 310
BC Extra | Sep 10, 2019
Company News

Sept. 10 Company Quick Takes: Lexicon, Sanofi part ways on diabetes drug; plus Mesoblast-Gruenenthal, Mateon-WideTrial, Intra-Cellular

Sanofi to pay Lexicon $260M as Zynquista ends  Sanofi (NASDAQ:SNY) will pay Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) $208 million up front plus $52 million over the next 12 months as part of the companies’ agreement to...
BC Week In Review | Oct 6, 2017
Clinical News

Mateon discontinuing Zybrestat on Phase II/III ovarian cancer data

Mateon Therapeutics Inc. (OTCQX:MATN) discontinued development of Zybrestat fosbretabulin (combretastatin A4P, CA4P) after data from the first 70 platinum-resistant ovarian cancer patients enrolled in the Phase II/III FOCUS trial showed Zybrestat in combination with physician’s...
BC Week In Review | Sep 1, 2017
Clinical News

Mateon reports interim Phase II/III data for Zybrestat in ovarian cancer

Mateon Therapeutics Inc. (OTCQX:MATN) reported data from a second scheduled interim analysis of the first 40 patients with platinum resistant ovarian cancer in the Phase II/III FOCUS trial of Zybrestat fosbretabulin (combretastatin A4P, CA4P) to...
BC Week In Review | May 19, 2017
Financial News

Mateon proposes $8M follow-on

On May 11, cancer company Mateon Therapeutics Inc. (OTCQX:MATN) proposed to raise $8 million in a follow-on underwritten by H.C. Wainwright. Mateon Therapeutics Inc. (OTCQX:MATN), South San Francisco, Calif. ...
BC Innovations | May 16, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture studies suggest that artificial vesicles loaded with Zybrestat fosbretabulin and doxorubicin could help treat doxorubicin-resistant breast cancer. The artificial vesicles consisted of amphiphilic block co-polymers loaded with Zybrestat fosbretabulin and...
BC Week In Review | Apr 28, 2017
Clinical News

Fosbretabulin: Ph I Study MCC-2016-088 started

Mateon said investigators at the University of Kentucky (Lexington, Ky.) began the open-label, U.S. Phase I Study MCC-2016-088 to evaluate IV fosbretabulin plus Afinitor everolimus for 12 weeks in about 30 patients who progressed following...
BC Week In Review | Jan 27, 2017
Clinical News

Zybrestat: Final Ph II Study OX4218 data

Final data from the open-label, U.S. Phase II Study OX4218 in 18 patients with well-differentiated, low-to-intermediate-grade, unresectable, recurrent or metastatic PNETs or GI-NETs showed that 60 mg/m 2 IV Zybrestat on days 1, 8 and...
BC Week In Review | Jul 11, 2016
Clinical News

Fosbretabulin: Phase II/III started

Mateon began the double-blind, placebo-controlled, U.S. Phase II/III FOCUS trial to evaluate 60 mg/m 2 CA4P on days 1 and 15 of a 28-day cycle plus physician’s choice of chemotherapy plus Avastin bevacizumab in about...
BC Week In Review | Nov 23, 2015
Clinical News

Fosbretabulin: Preliminary Phase Ib data

Preliminary data from 9 evaluable patients with advanced recurrent ovarian cancer in the dose-escalation Phase Ib portion of the open-label, U.K. Phase Ib/II PAZOFOS trial showed that once-weekly 45-60 mg/m 2 IV Zybrestat for 3...
BC Week In Review | Nov 2, 2015
Clinical News

OXi4503 combretastatin A1 di-phosphate: Phase Ib/II started

OxiGene began an open-label, U.S. Phase Ib/II trial to evaluate OXi4503 as a single agent and in combination with intermediate-dose cytarabine. The dose-escalation Phase Ib portion will enroll up to 27 patients and the Phase...
Items per page:
1 - 10 of 310